Skip to main content
BAX
NYSE Industrial Applications And Services

Baxter Beats on Q3 Sales of $2.98B, Raises Full-Year 2026 Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$26.74
Mkt Cap
$13.163B
52W Low
$15.73
52W High
$30
52W Position info
70% above low
Off High info
11% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

BAX sits 70% above its 52-week low of $15.73 on elevated volume (1.9× avg).

Summary

Baxter posted Q3 sales of $2.98 billion, up 5% organic, with adjusted EPS of $0.58, and raised its full-year 2026 sales and adjusted EPS outlook.


Key Events · Earnings and Guidance · BAX

  • Q3 Sales Rise 5% to $2.98B

    Worldwide sales of approximately $2.98 billion increased 5% on both a reported and organic basis, with growth across all segments and divisions.

  • Adjusted EPS Falls 16% on Tax Rate

    GAAP diluted EPS was $0.57 and adjusted diluted EPS was $0.58, down 16% year over year due to a higher effective tax rate.

  • Full-Year 2026 Outlook Raised

    Reported sales growth guidance raised to 4%-5% from 3%-4%, organic growth to 3%-4% from 2%-3%, and adjusted diluted EPS to $2.05-$2.15 from $1.95-$2.15.

  • Free Cash Flow and Debt Paydown

    Free cash flow was $448 million in the quarter and $705 million year-to-date; the company completed a $600 million cash tender offer, retiring $864 million of debt.


Analysis · BAX · Industrial Applications And Services

Baxter grew third-quarter sales 5% on both a reported and organic basis to $2.98 billion, with growth in every segment and division, and GAAP diluted EPS of $0.57. The company raised its full-year outlook: reported sales growth to 4%-5% from 3%-4%, organic growth to 3%-4% from 2%-3%, and adjusted diluted EPS to $2.05-$2.15 from $1.95-$2.15. Adjusted EPS of $0.58 fell 16% year over year on a higher effective tax rate, so the raise is a revenue and cash story rather than a margin recovery. Free cash flow of $448 million in the quarter and $705 million year-to-date, plus $864 million of debt retired in the quarter, supports the deleveraging and investment-grade credit objectives management has been pursuing.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BAX was trading at $26.74 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $15.73 to $30.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BAX - Latest Insights

BAX
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $25.35 info
Change: +$2.41 (+11%) info
Market Cap: $13.353B info
BAX
Oct 29, 2026, 8:06 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $25.35 info
Change: -$0.6497 (-2%) info
Market Cap: $13.353B info
BAX
Oct 29, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.50
Real-time Price: $25.35 info
Change: -$1.15 (-4%) info
Market Cap: $13.353B info
BAX
Aug 19, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.20
Real-time Price: $25.35 info
Change: -$0.8497 (-3%) info
Market Cap: $13.353B info
BAX
Aug 18, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $25.88
Real-time Price: $25.35 info
Change: -$0.5297 (-2%) info
Market Cap: $13.353B info